Trial Details
COMPLETEDBasic Information
| Clinical ID | c2688 |
|---|---|
| Identifier | NCT03105128 |
| Trial Title | A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease |
| Trial URL | Visit Original Page |
Study Information
| Study Results | YES |
|---|---|
| Conditions | Crohn's Disease |
| Interventions | DRUG: placebo for risankizumab|DRUG: risankizumab IV|DRUG: risankizumab SC |
Participant Information
| Sponsor | AbbVie |
|---|---|
| City | Phoenix |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | CHILD, ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE3 |
Time Information
| Start Date | 2017-05-10 |
|---|---|
| Primary Completion Date | 2020-11-09 |
| Completion Date | 2021-04-14 |